A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo

The targeted delivery of interleukin-2 to the tumor is gaining attention as an avenue to potentiate the action of T and NK cells at the site of disease. We have previously described the fusion of the L19 antibody, specific to the EDB domain of fibronectin, with human interleukin-2, using a non-coval...

Descripción completa

Detalles Bibliográficos
Autores principales: Ongaro, Tiziano, Gouyou, Baptiste, Stringhini, Marco, Corbellari, Riccardo, Neri, Dario, Villa, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566808/
https://www.ncbi.nlm.nih.gov/pubmed/33110477
http://dx.doi.org/10.18632/oncotarget.27726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566808/
https://www.ncbi.nlm.nih.gov/pubmed/33110477
http://dx.doi.org/10.18632/oncotarget.27726

Ejemplares similares